The statin decision in primary prevention is a baseline-risk decision. The relative effect of a statin is roughly constant; the absolute benefit scales with how high the risk was to begin with (Baseline Risk and the Relative-Absolute Split). Two sources set the decision: USPSTF 2022 gives the efficacy magnitudes and a risk threshold; Nasir/MESA 2015 shows a zero coronary-calcium score re-stratifies about half of statin-eligible people into a range where the benefit is small.
Statin efficacy in primary prevention (USPSTF 2022)
A systematic review of 22 trials (mean follow-up 3.3 years, all enrolling ≥1 risk factor):
| Outcome | RR (95% CI) | Absolute risk difference |
|---|---|---|
| All-cause mortality | «0.92 [95% CI, 0.87 to 0.98]» | «−0.35%» |
| Composite CVD | «0.72 [95% CI, 0.64 to 0.81]» | «−1.28%» |
| Myocardial infarction | «0.67 [95% CI, 0.60 to 0.75]» | «−0.89%» |
| Stroke | «0.78 [95% CI, 0.68 to 0.90]» | «−0.39%» |
| CV mortality | «0.91 [95% CI, 0.81 to 1.02]» (NS) | «−0.13%» |
The relative effects are real and consistent; the absolute differences are already small in these higher-risk trial populations. Harms were reassuring — no increase in serious adverse events, myalgia, or (except high-intensity JUPITER, confined to those with diabetes risk factors) new diabetes.
The USPSTF decision rule — and where a low-risk person falls
The threshold is explicit, and it is a 10-year-risk threshold, because «the magnitude of benefit of statin use is proportional to a person’s estimated 10-year CVD risk»:
- 40–75 yr + ≥1 risk factor + 10-yr risk ≥10% → prescribe a statin (Grade B, «at least a moderate net benefit»).
- 7.5% to <10% → «selectively offer» (Grade C, «at least a small net benefit»); «The likelihood of benefit is smaller in this group».
- <7.5%, or ≥76 yr → no recommendation / insufficient evidence.
So a primary-prevention person well below 7.5% 10-year risk is not a statin candidate by USPSTF at all — the drug question is closed by the baseline risk before any imaging is considered. (Two carve- outs USPSTF names: this does «not pertain to adults with familial hypercholesterolemia or an LDL-C level greater than 190 mg/dL» — those are treated regardless.) USPSTF scores risk with the Pooled Cohort Equations, which it concedes overpredict in many populations.
USPSTF does not use CAC: it «addressed the use of coronary artery calcium score for CVD risk assessment in a separate recommendation» — i.e. deliberately kept it out of the statin rule.
The power of zero (Nasir / MESA 2015)
Where a body does allow CAC, a zero score moves the decision. In 4,758 MESA adults (45–84 yr, median 10.3-yr follow-up), applying the 2013 ACC/AHA thresholds recommended 50% for statins and considered 12% more — and CAC re-stratified them sharply:
- 58% of the whole cohort, and 44% of the statin-eligible, had CAC = 0. Among statin-eligible people with CAC=0 the ASCVD rate was «4.2 per 1,000 person-years», versus «11.2 per 1,000 person-years» with any CAC. In the recommended group specifically, CAC=0 carried «5.2 ASCVD events/1,000 person- years»; in the considered group, «1.5 per 1,000 person- years».
- Estimated 10-year NNT (applying an assumed 30% relative reduction to the observed rates): in the recommended group, 64 for CAC=0 vs 28 for CAC>100; in the considered group, 223 vs 46 [EXTRACTED (Nasir - Coronary Artery Calcium Statin Candidates MESA 2015) chunk 01, Table 3 — the “¼ 0” spans are OCR for ”= 0”].
- The headline: «the absence of CAC reclassifies approximately one-half of candidates as not eligible for statin therapy», resting on the principle that «the net benefit from treatment is directly proportional to the absolute risk».
The honesty on both sides — this is not a settled rule
-
Nasir’s NNT is modeled, not measured. It multiplies observed CAC-stratified event rates by a borrowed 30% relative reduction (from a Cochrane statin meta-analysis), not by a statin effect measured within a CAC-randomized trial. The authors say so: whether a «CAC-based strategy versus guideline-based recommendations for statin selection… will have a favorable impact on outcomes… needs to be critically tested by well-designed comparative-effectiveness clinical studies.» No RCT has randomized statins by CAC.
-
CAC=0 is low risk, not no risk. 4.2/1,000 py is not zero, and NNT 64 is not infinity — a CAC=0 statin candidate still has some modeled benefit. In diabetes, CAC=0 still carried 4.9/1,000 py (NNT 69), so the de-risking is weaker there.
-
The 30% figure ties the two sources together and they agree. Nasir’s assumed relative reduction and USPSTF’s measured composite-CVD effect are the same quantity, and they match:
Parameter Nasir (assumed) USPSTF (measured) Same quantity? Statin relative reduction, composite CVD 30% (RR 0.70) «0.72 [95% CI, 0.64 to 0.81]» (28%) Yes — Nasir’s input is consistent with USPSTF’s trial estimate -
Population bounds: MESA is 45–84 (so it says nothing about adults <45) and may select healthier volunteers; USPSTF’s ARDs come from trial populations enriched for risk factors.
The unresolved divergence — lodged, not adjudicated
Whether CAC should guide the statin decision is contested across guidance families, and the evidence does not settle it (no RCT):
- USPSTF keeps CAC out of the statin rule (insufficient evidence, separate recommendation).
- ESC allows CAC as a Class IIb modifier around thresholds (Risk Modifiers - When Extra Information Changes a Risk Estimate).
- ACC/AHA and the MESA community use CAC=0 to defer statins in the grey zone (this page’s Nasir data is that case).
This is a genuine joined-issue candidate (risk-score-threshold vs imaging-guided allocation) but is not adjudicated here — it AWAITS a source that either randomizes CAC-guided treatment or is an independent institutional appraisal of the imaging-vs-score question.
Decision relevance
- Get the 10-year risk first; the threshold is the decision. Below ~7.5%, USPSTF says not a statin candidate, and CAC only reinforces deferral (a low-risk person is very likely CAC=0 anyway).
- In the grey zone (≈7.5–20%), a zero CAC roughly halves-to-quarters the absolute benefit (NNT 64 vs 28) and is a legitimate deferral input where a body allows it — but the deferral rests on modeled, not trial, benefit, so it belongs in shared decision-making, not an automatic rule.
- CAC=0 de-risks the DECISION, not the biology. ApoB/LDL remain causal; a high or rising ApoB, a high Lp(a), or familial hypercholesterolemia can still warrant treatment regardless of a zero score, and FH is explicitly carved out of the whole framework.
- The statin is the pharmacotherapy comparator to the lifestyle lipid lever — the lipid-axis analogue of Semaglutide for Cardiovascular Risk in Obesity on the weight axis. For a low-risk, CAC=0 person the realistic alternative to a statin is lifestyle plus monitoring, not nothing and not a drug with a fraction-of-a-percentage-point absolute benefit.
Limits
- The CAC-guided-statin question has no RCT — the standing open-loop (R1) problem in a sharp form.
- Nasir is one observational cohort with a modeled NNT; USPSTF is a strong systematic review but its ARDs are population-specific and it declines to rule on CAC.
- Neither source quantifies the CAC=0 negative predictive value by age band below 45 — the gap Risk Modifiers - When Extra Information Changes a Risk Estimate already flagged.